ClinicalTrials.gg
Active, not recruitingNCT07042594Updated Nov 10, 2026

Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants

A Phase 1 interventional study of RBD1119 and Placebo in Healthy Volunteers, sponsored by Suzhou Ribo Life Science Co. Ltd.. Active, not recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Suzhou Ribo Life Science Co. Ltd. · Phase 1, Interventional, and Treatment

How we know

Updated Nov 10, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Randomized, Single-blind, Placebo-Controlled Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of Subcutaneously Administered RBD1119 in Healthy Participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Suzhou Ribo Life Science Co. Ltd. is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  • Male or female healthy participants (non- only), aged 18 to 65 years at screening, inclusive.
  • (BMI) between 18 and 32 kg/m2, inclusive
  • , Prothrombin time (PT), INR, thrombin time (TT) within normal reference range (as per the local laboratory).
  • Haematology results within normal range, unless deemed not by the Principal Investigator or delegate. count however must be within normal range per the local laboratory reference ranges.
  • Healthy as determined by no clinically significant findings by the Principal Investigator or delegate in medical history, vital signs, physical examination, clinical laboratory assessments, and 12-lead (ECG).

Main Exclusion Criteria:

  • Any uncontrolled or serious disease that may interfere with participation in the clinical trial and/or put the participant at significant risk (according to Principal Investigator or delegate's judgment) if he/she participates in the clinical trial.
  • History or presence of cardiovascular disease (including peripheral artery and cerebrovascular disease).
  • Systolic blood pressure (SBP) is less than 90 or greater than 140 mmHg and/or diastolic blood pressure (DBP) is less than 50 or greater than 95 mmHg after 10 minutes of supine rest, unless determined by the Principal Investigator or delegate to be not clinically significant.
  • Diagnosis of diabetes mellitus, history of gestational diabetes that has not been fully resolved is not permitted.
  • History or presence of:

    • Bleeding disorder(s) and/or at risk of bleeding, including relevant familial history, such as Hemophilia A, Hemophilia B, Wiskott-Aldrich syndrome, von Willebrand disease (vWD);
    • Clinically significant anemia, in the opinion of the Principal Investigator or delegate;
    • Thromboembolic diseases;
    • Bleeding in the gastrointestinal tract or central nervous system;
    • Anticipated need for oral surgery or tooth extractions during the trial period;
    • Bleeding in the genitourinary tract;
    • Gum disease or active gum bleeding;
    • Planned surgery during the trial period.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    RBD1119 SAD experimental group

    Subjects in SAD experimental groups will receive a single subcutaneous injection of RBD1119 on Day 1.

    Drug: RBD1119

  • Placebo comparator
    Placebo SAD group

    Subjects in SAD placebo groups will receive a single subcutaneous injection of placebo on Day 1

    Drug: Placebo

Interventions

  • DrugRBD1119

    Subcutaneously Administered RBD1119 in Healthy Subjects.

  • DrugPlacebo

    Subcutaneously Administered Placebo in Healthy Subject.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0

    Time frame: Up to Day 85

Secondary outcomes

  1. Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0

    Time frame: After day 85

  2. To characterize the pharmacokinetics (PK) as maximum plasma concentration (Cmax) of RBD1119 in healthy participants

    Time frame: Up to 48 hours post-dose

  3. To evaluate the pharmacodynamics (PD) effect of RBD1119 as percentage change from baseline in intrinsic coagulation pathway related antigen levels in healthy participants.

    Time frame: Up to Day 169.

  4. To characterize the pharmacokinetics (PK) as Time to reach Cmax (Tmax) of RBD1119 in healthy participants

    Time frame: Up to 48 hours post-dose

  5. To characterize the pharmacokinetics (PK) as area under the plasma concentration-time curve from the time zero to the last measurable concentration (AUC0-t) of RBD1119 in healthy participants

    Time frame: Up to 48 hours post-dose

  6. To characterize the pharmacokinetics (PK) as area under the plasma concentration-time from time zero to infinity (AUC0-inf) of RBD1119 in healthy participants

    Time frame: Up to 48 hours post-dose

  7. To characterize the pharmacokinetics (PK) as apparent terminal elimination half-life (t1/2) of RBD1119 in healthy participants

    Time frame: Up to 48 hours post-dose

  8. To evaluate the pharmacodynamics (PD) effect of RBD1119 as percentage change from baseline in intrinsic coagulation pathway related activity levels in healthy participants.

    Time frame: Up to Day 169.

  9. To evaluate the pharmacodynamics (PD) effect of RBD1119 as percentage change from baseline in APTT in healthy participants.

    Time frame: Up to Day 169.

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2025 to primary completion in Aug 2026, 11 months.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Apr 2027, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2025
First posted
Jun 29, 2025
StartActual
Aug 26, 2025
Primary completionActual
Aug 5, 2026
CompletionEst.
Apr 2027was Sep 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Sep 2026→Apr 2027
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Study completion Sep 2026→Apr 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07042594
Responsible party
Sponsor
First posted
Jun 29, 2025
Start date
Aug 26, 2025
Primary completion
Aug 5, 2026
Completion
Apr 2027 (estimated)
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion